Provectus Biopharma (NYSE:PVCT) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 2,487,008 shares, a decrease of 13.0% from the August 31st total of 2,858,468 shares. Currently, 1.2% of the company’s stock are sold short. Based on an average trading volume of 3,843,492 shares, the days-to-cover ratio is presently 0.6 days.
Provectus Biopharma (NYSE:PVCT) opened at 0.1042 on Tuesday. The firm’s market capitalization is $22.18 million. The stock has a 50 day moving average of $0.16 and a 200-day moving average of $0.31. Provectus Biopharma has a 1-year low of $0.09 and a 1-year high of $0.60.
About Provectus Biopharma
Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.
Receive News & Ratings for Provectus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.